Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy

Lung Cancer

Volumn 48, Issue 3, 2005, Pages 379-387

  Novello, S ^a   Kielhorn, A ^b   Stynes, G ^c   Selvaggi, G ^a   De Marinis, F ^d   Maestri, A ^e   Foggi, P ^f   Tilden, D ^c   Tonato, M ^g   Crino L ^e   Rinaldi, M ^f   Migliorino, A M ^d   Scagliotti, G V ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b ELI LILLY AND COMPANY   (United States)

^c M TAG   (United Kingdom)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e BELLARIA HOSPITAL   (Italy)

^f REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^g Policlinico Hospital   (Italy)

Author keywords

Chemotherapy; Cost minimisation; Gemcitabine; Non small cell lung cancer; Paclitaxel; Pharmacoeconomics; Vinorelbine

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; COST MINIMIZATION ANALYSIS; DATA BASE; DISEASE COURSE; DRUG COST; DRUG EFFICACY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; ITALY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW; SURVIVAL;

EID: 21044434477     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.11.014     Document Type: Article

References (29)

1. D. Mather, S.D. Sullivan, and T.V. Parasuraman Beyond survival: economic analyses of chemotherapy in advanced inoperable NSCLC Oncology (Huntingt) 12 1998 199 209
2. P.C. Hoffman, A.M. Mauer, and E.E. Vokes Lung cancer Lancet 355 2000 479 485
3. D.S. Ettinger Is there a preferred combination chemotherapy regimen for metastatic non-small cell lung cancer? Oncologist 7 2002 226 233
4. D.M. Parkin, P. Pisani, and J. Ferlay Global Cancer Statistics CA Cancer J Clin 49 1999 33 64
5. A. Szczepura Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer Lung Cancer 38 2002 S21 S28
6. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909.
7. A. Clegg, D.A. Scott, P. Hewitson, M. Sidhu, and N. Waugh Clinical and cost-effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review Thorax 57 2002 20 28
8. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandler, and J. Krook Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98 (for the Eastern Cooperative Oncology Group)
9. G.V. Scagliotti, F. De Marinis, M. Rinaldi, L. Crino, C. Gridelli, and S. Ricci Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 2002 4285 4291 (for the Italian Lung Cancer Project)
10. P. Comella, G. Frasci, N. Panza, L. Manzione, G. De Cataldis, and R. Cioffi Randomised trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group J Clin Oncol 18 2000 1451 1457
11. A.B. Sandler, J. Nemunaitis, C. Denham, J. von Pawel, Y. Cormier, and U. Gatzemeier Phase III trial of gemcitabine plus cisplatin vs. cisplatin alone in patients with locally advanced or metastatic non-small cell lung cancer J Clin Oncol 18 2000 122 130
12. C. Sederholm Gemcitabine vs. gemcitabine/carboplatin in advanced non-small-cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group Semin Oncol 29 3 Suppl. 9 2002 50 54
13. P. Kosmidis, N. Mylonakis, C. Nicolaides, C. Kalophonos, E. Samantas, and J. Boukovinas Paclitaxel plus carboplatin vs. gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial J Clin Oncol 20 2002 3578 3585
14. P. Bonomi, K. Kim, D. Fairclough, D. Cella, J. Kugler, and E. Rowinsky Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin vs. etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial J Clin Oncol 18 2000 623 631
15. A.J. Wozniak, J.J. Crowley, S.P. Balcerzak, G.R. Weiss, C.H. Spiridonidis, and L.H. Baker Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group Study J Clin Oncol 16 1998 2459 2465
16. J.P. Van Meerbeeck, E. Smit, P. Lianes, F. Schramel, M. Lenz, and C. Debruyne A EORTC randomized phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 20 2001 308a (for the Italian Lung Cancer Project)
17. K. Kelly, J. Crowley, P.A. Bunn Jr., C.A. Presant, P.K. Grevstad, and C.M. Moinpour Randomised phase III trial of paclitaxel plus carboplatin vs. vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer. A Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
18. M. Lees, M. Aristides, N. Maniadakis, J. McKendrick, N. Botwood, and D. Stephenson Economic evaluation of gemcitabine alone or in combination with cisplatin in the treatment of nonsmall cell lung cancer Pharmacoeconomics 20 2002 325 337
19. Sources of unit costs of medical resources in Italy. Available from http://www.federfarma.it.
20. Ministero della Sanità (Italian Ministry of Health). Official negotiated prices of certain medications. Available from http://www. ministerosalute.it/medicinali.
21. F. Tediosi, G. Bertolini, F. Parazzini, G. Mecca, and L. Garattini Cost analysis of dialysis modalities in Italy Health Serv Manage Res 14 2001 9 17
22. Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G, on behalf of the Advisory Italian Board of the CODE-2 study. Social costs of diabetes type II in Italy: CODE-2 study. Pharmacoeconomics Italian Res Articles 2000;2:1-21.
23. C. Lucioni, R. Ravasio, and E. Concia Terapia empirica con antibiotici parenterali in pazienti ospedalizzati affetti da infezioni alle basse vie respiratorie: una valutazione farmacoeconomica Pharmacoeconomics Italian Res Articles 3 2001 37 47
24. J. Schiller, D. Tilden, M. Aristides, M. Lees, A. Kielhorn, and N. Maniadakis Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies Lung Cancer 43 2004 101 112
25. J.A. Sacristan, T. Kennedy-Martin, R. Rosell, F. Cardenal, A. Anton, and M. Lomas Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer Lung Cancer 28 2000 97 107
26. S.D. Ramsey, C.M. Moinpour, L.C. Lovato, J.J. Crowley, P. Grevstad, and C.A. Presant Economic analysis of vinorelbine plus cisplatin vs. paclitaxel plus carboplatin for advanced non-small-cell lung cancer J Natl Cancer Inst 94 2002 291 297
27. C.M. Moinpour, B. Lyons, P.K. Grevstad, L.C. Lovato, J. Crowley, and K. Czaplicki Quality of life in advanced non-small-cell lung cancer: results of a Southwest Oncology Group randomized trial Qual Life Res 11 2002 115 126
28. American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-9.
29. C.C. Earle, D. Coyle, and W.K. Evans Cost-effectiveness analysis in oncology Annu Oncol 9 1998 475 482